GARTISERTIB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H29F2N9O3
Molecular Weight	541.5531
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NN2C=C(F)C=NC2=C1C(=O)NC3=C(N4CCC(CC4)C(=O)N5CCN(CC5)C6COC6)C(F)=CN=C3

InChI

InChIKey=QAYHKBLKSXWOEO-UHFFFAOYSA-N

InChI=1S/C25H29F2N9O3/c26-16-9-30-23-20(22(28)32-36(23)12-16)24(37)31-19-11-29-10-18(27)21(19)34-3-1-15(2-4-34)25(38)35-7-5-33(6-8-35)17-13-39-14-17/h9-12,15,17H,1-8,13-14H2,(H2,28,32)(H,31,37)

HIDE SMILES / InChI

Approval Year

C_max

Value	Dose	Analyte	Population
376 ng/mL CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	450 mg single, oral dose: 450 mg route of administration: Oral experiment type: SINGLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
342 ng/mL CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	450 mg 2 times / week multiple, oral dose: 450 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
516 ng/mL CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	700 mg single, oral dose: 700 mg route of administration: Oral experiment type: SINGLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
675 ng/mL CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	700 mg 2 times / week multiple, oral dose: 700 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
395 ng/mL CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	1050 mg single, oral dose: 1050 mg route of administration: Oral experiment type: SINGLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
328 ng/mL CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	1050 mg 2 times / week multiple, oral dose: 1050 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
576 ng/mL CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
486 ng/mL CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	1200 mg 2 times / week multiple, oral dose: 1200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
265 ng/mL CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	350 mg 2 times / day multiple, oral dose: 350 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
948 ng × h/mL CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	450 mg single, oral dose: 450 mg route of administration: Oral experiment type: SINGLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
809 ng × h/mL CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	450 mg 2 times / week multiple, oral dose: 450 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1830 ng × h/mL CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	700 mg single, oral dose: 700 mg route of administration: Oral experiment type: SINGLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2670 ng × h/mL CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	700 mg 2 times / week multiple, oral dose: 700 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1390 ng × h/mL CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	1050 mg single, oral dose: 1050 mg route of administration: Oral experiment type: SINGLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1550 ng × h/mL CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	1050 mg 2 times / week multiple, oral dose: 1050 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2220 ng × h/mL CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1880 ng × h/mL CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	1200 mg 2 times / week multiple, oral dose: 1200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
703 ng × h/mL CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	350 mg 2 times / day multiple, oral dose: 350 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
2.22 h CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	450 mg single, oral dose: 450 mg route of administration: Oral experiment type: SINGLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.19 h CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	450 mg 2 times / week multiple, oral dose: 450 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3.33 h CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	700 mg single, oral dose: 700 mg route of administration: Oral experiment type: SINGLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3.11 h CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	700 mg 2 times / week multiple, oral dose: 700 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.61 h CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	1050 mg single, oral dose: 1050 mg route of administration: Oral experiment type: SINGLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3.6 h CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.37 h CLINICAL TRIAL https://classic.clinicaltrials.gov/ct2/show/NCT02278250	350 mg 2 times / day multiple, oral dose: 350 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VX-803 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Name

Type

Language

GARTISERTIB

Official Name

English

2-AMINO-6-FLUORO-N-(5-FLUORO-4-(4-((4-(OXETAN-3-YL)PIPERAZIN-1-YL)CARBONYL)-1-PIPERIDYL)-3-PYRIDYL)PYRAZOLO(1,5-A)PYRIMIDINE-3-CARBOXAMIDE

Preferred Name

English

VX-803

Code

English

PYRAZOLO(1,5-A)PYRIMIDINE-3-CARBOXAMIDE, 2-AMINO-6-FLUORO-N-(5-FLUORO-4-(4-((4-(3-OXETANYL)-1-PIPERAZINYL)CARBONYL)-1-PIPERIDINYL)-3-PYRIDINYL)-

Systematic Name

English

gartisertib [INN]

Common Name

English

M 4344 [WHO-DD]

Common Name

English

M-4344

Code

English

Code System Code Type Description

PUBCHEM

86720912